ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
1,2,Scan abnormal,Imaging procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
2,1,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
3,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
4,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
4,4,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
5,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
5,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
5,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
6,1,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
6,2,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
6,3,Hepatic artery embolism,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
6,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
6,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
6,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
6,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
6,8,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
6,9,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
7,1,Acute promyelocytic leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
8,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
8,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
8,3,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
9,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,Y
10,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
11,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
12,1,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
13,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
13,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
13,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
13,5,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
13,6,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
14,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
14,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
14,3,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
14,4,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
14,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
15,1,Gastroenteropancreatic neuroendocrine tumour disease,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
15,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
15,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
15,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
16,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
16,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
16,4,Pancreatic polypeptide level decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
16,5,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
16,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
17,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
17,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
17,3,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
18,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
18,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
18,3,Dental caries,Dental and periodontal infections and inflammations,Dental and gingival conditions,Gastr,N
18,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
18,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
18,6,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,7,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
18,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
18,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
18,10,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
18,11,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
18,12,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
18,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
18,14,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
19,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
19,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
19,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
19,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
19,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
19,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
19,7,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
19,8,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
20,1,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
20,2,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
20,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
20,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
20,6,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
20,7,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
21,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
21,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
21,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
22,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
22,2,Oesophageal varices haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
23,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
24,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
25,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
26,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
27,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
28,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
29,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
30,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
31,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
31,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
31,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
32,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
33,1,Hepatic necrosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
34,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
35,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
36,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
37,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
38,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
39,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
40,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
41,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
41,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
42,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
43,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
44,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
44,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
45,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
46,1,Administration site extravasation,Administration site reactions NEC,Administration site reactions,Genrl,N
47,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
48,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
49,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,2,Gastroenteropancreatic neuroendocrine tumour disease,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
49,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
49,4,Metastases to bone marrow,Metastases to specified sites,Metastases,Neopl,N
50,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
51,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
52,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,2,Gastroenteropancreatic neuroendocrine tumour disease,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
52,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
52,4,Metastases to bone marrow,Metastases to specified sites,Metastases,Neopl,N
53,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
54,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
55,1,Suspected COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
56,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
57,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
58,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
58,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
59,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
59,2,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
60,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
61,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
62,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
63,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
63,2,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
64,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
65,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
66,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
67,1,Suspected COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
68,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
69,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
70,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
71,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
72,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
73,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
74,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
75,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
76,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
77,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
78,1,Abnormal faeces,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
78,2,Bowel movement irregularity,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
78,3,Defaecation urgency,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
79,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
80,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
80,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
81,1,Full blood count,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
82,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
83,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
84,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
84,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
85,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
85,2,Gastroenteropancreatic neuroendocrine tumour disease,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
85,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
85,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
86,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
86,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
87,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
88,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
89,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
89,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
90,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
91,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
92,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
93,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
93,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
93,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
94,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
95,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
96,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
96,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
96,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
97,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
97,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
97,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
98,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
99,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
100,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
100,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
101,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
102,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
103,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
103,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
104,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
105,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
106,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
106,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
106,3,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
106,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
107,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
107,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
108,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
108,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
108,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
108,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
109,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
109,2,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
109,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
109,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
109,5,Product contamination,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
109,6,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
110,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
110,2,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
111,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
111,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
112,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
113,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
113,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
114,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
114,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
115,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
116,1,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
117,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
118,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
119,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
120,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
121,1,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
121,2,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
122,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
123,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
124,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
124,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
125,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
126,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
127,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
128,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
129,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
130,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
131,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
132,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
132,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
133,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
133,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
134,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
135,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
136,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
136,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
137,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
137,2,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
138,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
138,2,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
139,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
140,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
141,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
142,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
143,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
144,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
145,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
146,1,Fracture,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
146,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
147,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
148,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
149,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
149,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
150,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
151,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
152,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
153,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
154,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
154,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
155,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
156,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
157,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
158,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
159,1,Imaging procedure abnormal,Imaging procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
160,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
160,2,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
161,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
162,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
163,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
164,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
165,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
166,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
167,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
168,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
169,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
170,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
171,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
172,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
172,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
173,1,Acute promyelocytic leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
174,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
175,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
176,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
176,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
176,3,Vipoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
177,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
178,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
179,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
180,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
181,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
182,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
183,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
183,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
183,3,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
183,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
183,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
184,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
184,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
184,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
185,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
185,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
185,3,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
186,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
186,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
186,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
186,4,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
187,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
188,1,Blood calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
188,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
188,3,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
188,4,Metastases to bone marrow,Metastases to specified sites,Metastases,Neopl,N
188,5,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
189,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
190,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
191,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
191,2,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
191,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
191,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
191,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
191,6,Radicular pain,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
191,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
191,8,Tumour flare,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
192,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
193,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
194,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
195,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
196,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
197,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
198,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
199,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
200,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
200,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
200,3,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
201,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
202,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
203,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
204,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
205,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
206,1,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
206,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
207,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
207,2,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
208,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
209,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
210,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
211,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
211,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
211,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
212,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
213,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
214,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
215,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
216,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
217,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
218,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
218,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
218,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
218,4,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
219,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
220,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
221,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
221,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
221,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
222,1,Cardiac dysfunction,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
222,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
223,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
223,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
223,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
223,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
223,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
223,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
223,7,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
223,8,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
224,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
224,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
224,3,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
224,4,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
225,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
225,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
226,1,Marginal zone lymphoma recurrent,Marginal zone lymphomas NEC,Lymphomas non-Hodgkin's B-cell,Neopl,N
227,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
227,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
227,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
227,4,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
227,5,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
228,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
228,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
228,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
228,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
228,5,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
228,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
229,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
229,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
230,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
230,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
231,1,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
232,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
232,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
232,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
232,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
232,5,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
232,6,Pancreatic carcinoma metastatic,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
232,7,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
232,8,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
232,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
233,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
233,2,Headache,Headaches NEC,Headaches,Nerv,N
233,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
233,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
233,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
233,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
233,7,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
233,8,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
234,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
234,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
234,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
234,4,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
235,1,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
235,2,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
235,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
235,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
235,5,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
235,6,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
235,7,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
236,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
236,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
236,3,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
236,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
236,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
236,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
236,7,Liver abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
236,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
236,9,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
236,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
236,11,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
236,12,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
236,13,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
236,14,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
237,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
237,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
237,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
237,4,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
237,5,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
238,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
238,2,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
238,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
238,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
238,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
238,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
238,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
238,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
238,9,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
238,10,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
238,11,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
238,12,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
238,13,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
238,14,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
239,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
239,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
239,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
240,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
241,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
241,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
241,3,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
241,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
241,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
241,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
241,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
241,8,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
241,9,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
241,10,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
241,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
241,12,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
241,13,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
241,14,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
241,15,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
241,16,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
241,17,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
241,18,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
242,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
243,1,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
244,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
245,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
245,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
245,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
245,4,Urine flow decreased,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
245,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
246,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
246,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
246,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
247,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
248,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
249,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
249,2,Paraganglion neoplasm,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
249,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
250,1,Bone cancer metastatic,Bone neoplasms malignant (excl sarcomas),Skeletal neoplasms malignant and unspecified,Neopl,N
250,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
250,3,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
250,4,Paraganglion neoplasm,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
250,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
251,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
251,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
251,3,Paraganglion neoplasm,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
252,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
253,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
255,1,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
255,2,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
256,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
257,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
258,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
259,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
259,2,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
260,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
260,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
260,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
260,4,Insulinoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
260,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
260,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
260,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
261,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
261,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
261,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
262,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
262,2,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
262,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
262,4,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
262,5,Myelodysplastic syndrome,Myelodysplastic syndromes,Leukaemias,Neopl,N
262,6,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
262,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
262,8,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
263,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
263,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
263,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
263,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
263,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
264,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
264,2,Glioblastoma multiforme,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
265,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
265,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
265,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
265,4,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
266,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
267,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
268,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
269,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
270,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
271,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
272,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
273,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
274,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
275,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
276,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
277,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
278,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
279,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
280,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
281,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
282,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
283,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
284,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
285,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
285,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
286,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
287,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
287,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
288,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
289,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
289,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
290,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
291,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
293,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
294,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
295,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
296,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
296,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
297,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
298,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
300,1,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
